research on india_healthcare sector in india monthly update_january 2012

Healthcare Sector in India Monthly Update

January 2012

Top Story Relaunch of Urokinase by Cadila pharmaceutical aided by partnership Microbix India based Cadila pharmaceutical has entered into a profitable partnership with Canada based Microbix Biosystems to re‐launch a thrombolytic drug Urokinase. Microbix will take up the responsibility of providing the required manufacturing infrastructure, raw material, skilled personnel. On the other hand, Cadila has undertaken the responsibility of arranging the requisite funds for conducting the first

with

clinical trial that will be undertaken by Microbix and commercializing the product. The launch of the product is scheduled to be in 2014. The drug was first approved in the USA in 1978 for pulmonary embolism (blockage in the arteries supplying blood to the lungs) and coronary occlusion (blockage in the vessels which carry blood to the heart). Re‐launch of the drug will have a strong

l impact in the pharmaceutical industry that is most certain to penetrate in other globamarkets as well. Cadila Pharmaceuticals Ltd. is a large pharmaceutical company with its headquarters in Ahmedabad distributing products in over 50 countries. In 2011, Cadila ventured into a number of partnerships and acquisitions. In June 2011, it acquired US‐based esher Pharma, in July 2011 it acquired Bremer Pharma Gmbh with plans of xpansion in animal healthcare and finally, in December 2011 with Biochem. Ne News Update

General Frugal Engineering will drive the Indian medical world Frugal engineering is going to take India by a sweep in 2012. Various low cost

i gtechnologies are emerg ng that will enhance the quality of health services in eneral and for the rural Indians in particular. The joint winners for the Inclusive Innovation award by RA Mashelkar, former director‐general at the Council of Scientific and Industrial Research (CSIR) and National Research professor had developed a portable device to detect five eye diseases and a diaper that costs one‐tenth its current price. Johnson & Johnson has developed low‐cost knee implants and reusable staplers while Roche Diagnostics introduced a cardiovascular screening device for rural India and General Electric (GE) ortable ECG machines and other such devices. Frugality is simply not only about low ost rather it is the advancement and innovation that counts as much. pc

Healthcare – Monthly Update

Personal diagnosis to revolutionise the medical diagnosis industry Even with so much of medical advancement, in India still people die due to lack of correct and timely diagnosis of disease. Diseases that mostly prevalent nowadays are mainly lifestyle oriented, genetic or because of environmental factors. Genomics (personal diagnosis) comes as a solution to this which will provide knowledge of a person’s disease risk alongwith prediction of any forthcoming major disease, thereby enabling physicians to provide correct advice and regular monitoring incase of observation of any serious disease. The variations in DNA are studied by genotyping and once the respective genotypes are known complications can be identified. This happens to be a much inexpensive and reliable option than the high priced diagnostic tests. Ocimum Biosolutions of Hyderabad origin in India has built a strong base in the field of genomics and others are soon to offer such service. Rabies deaths soon to become history CPL Biologics (CPLB) a joint venture of Novavax, Inc. (USA) and Cadila Pharmaceuticals Ltd.(India) have made significant developments in the field of

vaccination in 2011 and has planned clinical studies for prevention of influenza and rabies in 2012 and 2013. CPLB has successfully completed positive preclinical immunogenicity studies of rabies G‐protein nanoparticle vaccine which was engineered by Novavax that has

recently been approved by Review Committee on Genetic Manipulation (RCGM), Indiato begin toxicology studies of this vaccine prior to initiating human clinical trials. CPLB has added another feather to its hat by acquiring validation of its state‐of‐the‐art manufacturing facility in Dholka, India by installation of single‐use vaccine ioprocessing system that can produce large volume of novel vaccine doses every ear. by Project ‘Tarang’ will make hearing aid devices affordable The Centre for Development of Advanced Computing (C‐DAC) has undertaken the project ‘Tarang’ for developing hearing aid devices at a price as low as INR 2000 to INR 3000. The project ‘Tarang’ is an initiative of C‐DAC along with CMC Vellore, the All‐India Institute of Medical Sciences and others. Normally, such devices come at a price between INR10000 and INR 100000 which is not affordable for most Indian customers. The project is being financed by the Department of Information Technology (DIT) and is in the stage of field trials. The project was undertaken by the recommendation of an Inter‐Ministerial Group to prove Indian engineering capabilities without compromising on technology and quality. The device will be unique as it will be re‐programmable so that a user will not have to purchase a separate device if the hearing ability fluctuates over time. This initiative was undertaken all the more to reduce the import bill that comprises 80 per cent of the INR 134 bn Indian medical electronics market.


MedPal marketing pla form to benefit healthcare providers and consumers Praxis Healthcare has launched for the first time in India a marketing platform ‘MedPal’ that provides low cost but effective solutions for healthcare providers to reach the consumers. Health cards sold by MedPlan will enable access to healthcare information and facilities within reach of health focused consumers that will help reduce their medical expenses to a great extent. This will also reduce the marketing costs of healthcare providers like hospitals, diagnostics, polyclinics and even doctors who are willing to promote themselves. Through MedPal, Praxis plans to establish atleast 6000 medical centres and pharmacy network to its patients across India. It is

t

t

expecting lucrative offers flow from top hospitals, tele consultants, elemedicine network providers, information providers on diseases and drugs. Praxis Healthcare, Mumbai are experts in providing hospital consulting services and llied healthcare requirements. Client base of Praxis include Asian Heart Institute, ulekha Hospital, Fortis Healthcare, The Apollo Clinic among several others. aZ Indian medicinal herbs prove to be useful to cure after effects of radiation The Defence Research and Development Organisation (DRDO) have developed a Tulsi (Indian Basil) based medicine to treat humans exposed to the harmful effects of radiation. The project is worth INR 0.7 mn. Basil is being used for the first time to

firsttreat damage caused by radiation. The round of clinical trial has been successful and is already in its second stage. The anti‐oxidant property of basil has the capability to repair damaged cells due to exposure to radiation. Other innovations by the Organisation include Aloe Vera based nti‐ frost bite cream ‘Alocal’ and herbal drink composed of fifteen different herbs hat help acclaimatising to rough weather condition prevailing in high altitudes. at Godrej InterioLINET Group alliance set to improve Indian hospital furniture Indian furniture manufacturer Godrej Interio has partnered with European hospital and nursing home beds manufacturer specialist LINET Group. The collaboration is with the motive to bring to India LINET range of hospital beds and allied furniture. They are to jointly develop healthcare products for Indian hospitals as well as set up a

roducts some amanufacturing centre for LINET's p distribution to of the profit ble Asian markets. The products that will be marketed in India are committed to ensure comfort and superior solutions for patient care. The products will be available in India from April 2012 in all metros wherein Godrej will focus on private and corporate hospitals. hereafter, it plans to make the furniture more affordable by indigenous production f some significant components of the furniture. To Uttar Pradesh soon to have new hospitals RG Stone Urology & Laparoscopy Hospital chain of Mumbai origin has planned to set up 12‐15 new hospitals in UP with 40‐45 beds in each, over the next two years. The hospital has planned to invest INR 1.2 bn for the project in UP. At all India level, the


hospital administration has planned to set up 50 new hospitals with a total investment plan of INR 5 bn. This project will focus on raising awareness about urology by running medical vans in remote belts of UP and Uttarkhand region and offering free medical consultation. RG tone is a well known group of hospitals having been certified by the Guinness Book f World Records for having first treated the largest kidney stone of the world. So Health Insurance in India becomes more accessible Cigna TTK Health makes recent entry in the health insurance market with the most innovative marketing strategy. It has plans to sell health insurance policies across the counter through local pharmacies. The health kit will feature simple schemes that do not require medical tests and the buyer can simply file in required documents online.

, The product will be marketed through its vast network of franchisees pharmacies and also their own stores. US based health service company, Cigna and one of India's leading Third Party Administrators providing services to health insurance policy holders, TTK Healthcare TPA Private Limited have entered into a joint venture to sell the Cigna TTK Health nsurance plans in India. In the venture Cigna holds a 26% stake while the remaining s held by TTK. ii Olympus Capital plans to invest in DM Healthcare Olympus Capital Holdings Asia, a leading independent middle market private equity firm is planning to make a huge investment in Gulf based healthcare service provider DM Healthcare. The amount of investment is quoted to be INR 5 bn. Olympus makes the investment with the motive of bringing DM Healthcare’s service network expansion in India. Also, it is taking the opportunity of purchasing a portion of India Value Fund shareholding in the company. The invested amount will enable M Healthcare to set up its upcoming 'Aster Medcity', which is expected to start perations in 2013 in Kochi. Do Serum Institute in plans to sell its international stakes Serum Institute has planned to sell off its international stakes held in Lipoxen Plc of the UK and Akorn Inc of the USA. Lipoxen is a bio‐pharma company while Akorn is a maker of sterile speciality pharmaceuticals. The stakes in the two companies were purchased each at INR 10 mn and Serum will be satisfied if it can offload the stake at cost price. This was because the deal could not earn Serum the expected profits. ence, Serum has decided to focus in its core business of vaccines and immuno‐iologicals and excel in the field globally. Hb


Jubilant Life Sciences and Eli Lilly to dissolve their JV Bangalore based Vanthys Pharmaceuticals‐ a joint venture by Jubilant Life Sciences and Eli Lilly has decided to call off their association for reasons undisclosed. Jubilant has decided to absorb the employees most of whom are scientists working for Vanthys.

Vanthys was formed in 2008 as a 50‐50 JV between the respective companies for developing molecules from the pre‐clinical to phase II stage trials in oncology, iabetes and cardiovascular segments. It was an approximately INR 352.47 mn nvestment deal for each of the 2 companies for a period of 3 years. di Da Vita purchases a stake in NephroLife USA based Da Vita Inc. has purchased a major stake in India based NephroLife company for an undisclosed amount. The new company will be called DaVita

a t oNephroLife. Da Vit showed its interes in India due t the high investment opportunities that Indian healthcare sector is presently generating. NephroLife with 9 centres in Bangalore is a kidney care company that provides operation in dialysis service and vascular surgery. NephroLife brings together expertise in Nephrology, Dialysis, Urology, Vascular Surgery, General Medicine, Psychology, Diet & Lifestyle Management and Diagnostics. DaVita Inc., is a FORTUNE 500® company, providing kidney care‐ delivering dialysis services to patients with hronic kidney failure and end stage renal disease. Da Vita is making its presence felt hrough domestic and international acquisitions and associations. ct HCG brings its cancer specialty hospital to Ahmedabad HealthCare Global (HCG) super‐specialty hospital has been recently inaugurated in Ahmedabad. The super specialty hospital is equipped with comprehensive cancer treatment facilities including medical, surgical and radiological oncology. The hospital has also installed an advanced radiation therapy technology called TrueBeam. HCG is headquartered in Bangalore and is South Asia's Largest Cancer Care Network hat operates across 22 centers. It has been consistently providing a vision for a better omorrow to over 30000 new patients annually for the past 20 years. tt Indoco and DPP collaborates to market Indoco products Indoco Remedies Ltd. has inked a JV with DSM Pharmaceutical Products (DPP) NV, a group company of Royal DSM NV. The deal pertains to DPP marketing and selling Indoco manufactured 8 Active Pharmaceutical Ingredients (API) in Austria along with other international markets. The deal amount though remains undisclosed. Austria based DPP is recognized as a global leader in health, nutrition and materials that connects its unique competences in Life Sciences and Materials Sciences to create solutions that nourish, protect and improve performance. Indoco Remedies Ltd. is a Mumbai based manufacturing and marketing of formulations (Finished Dosage Forms) and APIs company. It boasts of a well‐built brand portfolio of 135 products in various therapeutic segments, including high growth life style segments such as Anti‐iabetics, Cardiovascular, Central Nervous System, Musculo‐Skeletal, Nutrition and ental care.

DD


News Update

Regulatory India plans action to identify fake drugs Gujarat Food and Drugs Control Administration (GFDCA) is on its way to develop 'Quick Detection Kits' to keep a close watch and reduce time taken to identify fake drugs. The project happens to be a joint collaboration between GFDCA and Department of Health and Human Services which is the apex health body of the United States. Based on infra‐red spectroscopy a quick detection kit for screening of pharmaceutical products will be developed to save 36 to 72 hours which is normally required to test a drug. Three‐member team from Department of Health and Human Services will visit he Gujarat laboratory in February to discuss the possible techniques for the quick nalysis of the pharmaceutical products. ta Clinical Trials in India dwindle due to strict government regulations Out of 118,804 human trials in 178 countries only 2% trials are being conducted in India compared to 8% in China according to the US government’s clinical trial website. This is mainly due to the unethical practices that emerged during human drug trials, which prompted the Indian government to place strong regulations to check such malpractices. Government nod on such clinical trials has now become time consuming affair and the fear of unethical practice is resulting in poor sample size for tests. The Indian market size for clinical trials was estimated to be above INR 14 bn in 2009 having a CAGR of 30%. India was one of the fastest growing clinical research centres and was ahead mainly because of its low cost‐ almost 40‐60% lower than its ounterparts in developed countries and 10‐20% lower than other developing ountries. cc Medicure Inc. receives approval for conducting clinical trial in India Canada based pharmaceutical company Medicure Inc. has received approval for conducting clinical trial in India from the Drug Controller General of India. Medicure is in plans to conduct the phase II trial of TardoxalTM that can be used for the treatment of Tardive Dyskinesia (TEND‐TD) which is a common side effect of antipsychotic medications and is useful to treat schizophrenia and schizoaffective disorders. The trial is to be held at Schizophrenia Research Foundation, Chennai of which the enrollment procedure is slated to begin from Feb 2012. Medicure is a specialty pharmaceutical company that constantly strives in the mission to deliver the best in the field of commercialization and development of unique small olecule pharmaceuticals in the cardiovascular and neurological fields for unmet edical needs.

mm


PHARMEXCIL gets organized to solve national and global issues The Pharmaceutical Export Promotion Council of India has taken up an initiative to solve the various issues related to pharmaceutical exports and promotion. It has formed 5 global and 7 sectoral panels that will help in solving related issues in the domain of both international as well as national. The global panel will operate in CIS (Common wealth Independent States), Africa, LATAM (Latin America region), ASEAN (Association of South East Asian Nations) and regulated markets. The sectoral panel will be responsible to acquire information, make important announcements and create awareness among members about each sector. The sectors include include Foreign trade‐DGFT, SME (Small and Medium Enterprises), Ayush (Ayurveda, Unani,

g rSiddha and Homoeopathy), API/CRO/R&D/le al/IPR, Merchant trade, Bio Pha ma and Medical Devices. The rapid growth of the knowledge based Indian Pharma Industry led to the foundation of PHARMEXCIL. The activities of the Council are administered by Committee of Administration consisting of representatives from major Pharma industries in India like J B Chemicals & Pharmaceuticals Limited, Suven Life Sciences Limited, Dr. Reddy’s Laboratories, Aurobindo Pharma, Luipin, Ranbaxy, Novarties, Avantis, Ipca, Shasun, Sun Pharma, Zydus Cadila, Glowchem, Calyx etc., apart from Government officials from Central government and Government of Andhra Pradesh. dministrative support to the Council is extended by rich experienced personnel from arious fields like Government of India and the Pharma industry. Av Health Ministry goes slow in taking action against HPV vaccine Even though the phase‐IV post licensure trial of Human Papilloma Virus (HPV) vaccine resulted in death of a few subjects, the authoritiy has still not taken any strict action against the same. Out of 14091 girls who received the vaccine in Andhra Pradesh and 10686 girls in Gujarat, there was reported to be 7 deaths. The

ealth controversial trial had been listed by the H Ministry and is reported to be still under examination. Programme for Appropriate Technology in Heath (PATH) an NGO had initiated the clinical trial for HPV vaccine. The Indian Council of Medical Research (ICMR) and the State Governments of Andhra Pradesh and Gujarat were the collaborating partners. With emergence of certain irregularities, ICMR suspended the trial in Apr 2010. Further, as PATH followed up with requisite clarifications, in May 2010 the government allowed the 3rd phase of trial without further vaccinations. Both brands of HPV vaccine‐ Gardasil by Merck and Cervarix by GSK were used for the trial that esulted in the deaths. But since the deaths could not be proven to be due to the accination, the Health Ministry is still lagging behind in taking adequate action. rv


Indian generic pharma in an attempt to tap business in Japan The union commerce ministry of India in an attempt to encourage the Indian generic pharma industries is likely to enter into a protocol with the Japanese government. The union commerce ministry is likely to make a proposal for the same at the Convention on Pharmaceutical Ingredients (CPhI) to be held in Tokyo from March 21 to 23, 2012.

This is because the administ ation believes Japan an rovide i mense rading opportunity of Indian generic pharmaceuticals. PHARMEXCIL team will join the union commerce and industry minister Anand Sharma with other delegates to the convention to find reasonable opportunity of having closer trade relation under the Comprehensive Economic Partnership Agreement (CEPA) between India and Japan that was signed in August last year.

r c p m t

Emergency trauma centres in MumbaiPune Expressway The rising number of accidents in Mumbai‐Pune Expressway has led the All‐India Motor Transport Congress (AIMTC) to propose to the Maharashtra state government o set up emergency medical facilities at a distance of every 25kms along the highway. tThus, the 93kms long expressway must have 4 such rescue units. The plan has been drafted in which the AIMTC has proposed to collaborate with the government and carry out rescue operations by setting up emergency trauma centres ith doctors on the call, proper medical equipment and ambulances. The draft is yet o be submitted. wt News Update

Expansion Plans Cochlear implant comes as solution to performance failure of hearing aid yehi Institute of Medical Sciences and Research Centre in Bangalore have recently introduced the cochlear implant centre. A cochlear implant is an artificial hearing device which is designed to produce hearing sensation by electrical stimulation of nerves inside the inner ear thereby facilitating in hearing and proves beneficial when hearing aid fails. Availability of enhanced diagnostic facilities for hearing impairment enables medical intervention to be administered with least loss of time. The cochlear implant is beneficial as it does not require surgery and an auditory rehabilitation process is followed after the implant Widex India launches new products for hearing impediment Widex India, the subsidiary of Denmark based manufacturer of hearing aid devices, Widex A/S, has launched new products in the super series range. The new products, Widex Super 440 and Widex Super 220 have been specially designed for cases of profound hearing loss. With the launch of the new devices the company is expecting


to increase sale to 26,000 units this FY from the 20,000 units in the previous year. It also plans to add 8‐10 of its Senso Hearing Diagnostic Centres each year. Widex India was initially a joint venture between Widex Denmark and an Indian company but has now become a fully owned subsidiary of Widex Denmark.

Headquartered at Chandigarh it has a wide network of sales offices in Bangalore, Chandigarh, Chennai, Delhi, Kolkata, Mumbai and Pune. It specialises in the field of digital hearing aids. Opto Circuits to make a mark in the US cardiac monitoring device market Opto Circuits (India) Limited has been approved by the USFDA to sell 'MySense Heart' in the American markets. The approval was given after a thorough clinical trial of the product in the United States and New Zealand in late 2011. It is a low‐cost wearable cardiac monitor that helps in regular monitoring of cardiac patients and will be commercially available from early 2012. Opto Circuits is a multinational medical device company headquartered in Bengaluru and reaches across to150 nations of the world. Cardiac Science Corporation, the ubsidiary of Opto Circuits has acquired the approval from the USFDA in the evolutionary technology of managing the challenges of handling heart patients. sr Nova Medical signs MOU with a European healthcare chain A European healthcare chain is set to acquire 15% strategic stake of Nova Pulse, the In Vitro Fertilisation (IVF) arm of Nova Medical. Nova Medical Centres are renowned for its expertise in surgical care. Nova Pulse is valued at less than INR 3bn. With the emergence of the European chain recognised as the global leader in this segment, it is expected to bring about some expertise in the industry as India has no organised IVF providers. The Indian IVF market is currently worth INR 53.57 bn and is growing at a rate of 15% in which regional clinics are ruling the maximum share of the industry. Previously Nova Medical had signed MOU with Analjit Singh‐led Max Healthcare in last October to open daycare surgeries in Delhi region and has since then been on aggressive expansion plans worldwide. The parent firm of Nova in Bangalore has raised INR 7.5mn by issue of fresh shares. GTI group, New Enterprise Associates (NEA), Omani industrial group OMZEST and Mahesh Reddy, a doctor are the source of fund for the company. Health 3 Operations a joint initiative by Seed Healthcare Solutions and Health Information System Pune based Seed Healthcare Solutions (SHS) has collaborated with Jordan based Health Information Systems to expand their market to Middle East North African region for their hospital information management system (HIMS) software. It is a 50‐50 joint venture with the Health Information Systems investing INR 52.46mn while


SHS has provided their IP technology. This new venture will be known as Health 3 Operations. SEED Healthcare Solutions (SHS) is a software solutions company that provides highly feasible, easy to use Hospital Information Management System (HIMS) for the healthcare industry. Established in October 2006, it initiated its product sales in India since early 2007 and in 2008, SHS successfully expanded its market coverage to Middle East market.

Kalyani group and Ruby Hall Clinic tie up to launch a hospital Pune based Kalyani Group and Ruby Hall Clinic has joined hands to launch the Institute for Prostate Cancer. The institute is an effort towards betterment in research, diagnostics, treatment and education in the field of prostate cancer. It is Kalyani Group’s first initiative in the field of medicine and has been undertaken entirely with a philanthropic motive. The group has been able to rope in New York‐based Dr Ashutosh Tewari who has very recently been awarded the American Urological Association’s ‘Gold Cystoscope Award’. The Kalyani Group is a leading industrial house in India that focuses primarily on four sectors, namely Engineering Steel, Automotive & Non‐Automotive Components & Equipments, Renewable Energy & Infrastructure and Specialty Chemicals. Ruby Hall linic is Pune’s first and only nationally accredited hospital which specializes in an rray of clinical and diagnostic services. Ca TROP T to make cardiac care simpler Medical Diagnostics and Pharmaceuticals company Roche Diagnostics India Pvt. Ltd. and Chandigarh based pharmaceutical company Ind‐Swift Ltd.(ISL) has collaborated to promote TROP T. An innovation by RD (India) Pvt. Ltd., TROPONIN‐T helps to assess damage to heart muscle. It enables differentiation between chest pain and heart attacks through a simple blood test that provides reliable result in a matter of fifteen minutes. The tie up is primarily with the aim to create awareness amongst cardiologists, iabetologists, consulting physicians and other general practioners through its Strong ield Force. dF India gets high resolution MRI proof pacemaker and lead USA headquartered St. Jude Medical, Inc. has launched the Accent MRI™ pacemaker and Tendril MRI™ lead in India. The pacemaker and lead so devised comes with the guarantee of having no harmful impact on patients when undergoing high resolution MRI scans. This has been done specifically keeping in mind patients’ future medical requirements. The Accent MRI™ pacemaker comes with the provision of wireless telemetry and algorithms for the benefit of individual patients. The device comes with an MRI Activator™ that provides alternative option to programme the device to the appropriate MRI mode for use during the scan. he Madras Medical Mission in Chennai has already incorporated the device for its atient and is slowly being made available in other hospitals too. Tp


Russia A new market for Opto Circuit (India) subsidiary Criticare’s monitoring system Criticare System Inc. a subsidiary of Opto Circuit (India) has struck a lucrative deal with the popular hospitals of Tyumen Oblast province of Russia. Criticare is to supply and install nGenuity vital signs monitors and provide adequate training for the same. The contract has been secured by Criticare’s Russian distributor, Elmedica for an undisclosed amount.

Russian hospitals have adopted a modernization programme and currently hospitals n the cities of Zavodoukovsk, Yalutorovsk and Tyumen are the forerunners in doption of the modern day patient monitoring system from Criticare. ia Sohm Inc. sets up Nutraceutical Manufacturing unit in India North America based Sohm Inc. has successfully started its nutraceutical manufacturing operation in Ahmedabad from last month. The company has already started its commercial production of nutraceuticals along with Diorac, a unique probiotic anti‐diarrheal drug. The manufacturing unit built, has complied with all the norms of Dietary Supplement Health and Education Guidelines. The project has been undertaken keeping in mind US Food & Drug Administration and the Indian Food & Drug Administration initiatives in simplifying rules and regulations n the area of neutraceuticals. Also, with the growing popularity of Nutraceuticals due o a rapid change in lifestyle, Sohm has ventured into the field at an opportune time. it Pacific Biomarkers and Clinigene International collaborates to expand specialist service USA based Pacific Biomarkers and India based Clinigene International Limited has agreed to provide special biomarker and high‐end clinical trial laboratory needs for global pharmaceutical and biotechnology industry. The partnership will help initiate and expand Pacific Biomarkers network in India. Bangalore based Clinigene is a Contract Research Organisation that provides phases I and II clinical trial solution, central laboratory, immunoanalytical and data management services. Seattle based PBI is a biomarker laboratory and contract research service provider that supports pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in he areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and utrition. tn Biocon’s success in psoriasis treatment Biocon Ltd. has successfully completed the late stage clinical trial of its experimental drug‐ Itolizumab. Itolizumab is helpful in treating psoriasis (a chronic skin ailment). The trial was conducted among 200 persons and its effect was experienced after 28 weeks with a response rate of 46%. The drug was safe with an infection rate of about 10%. Itolizumab is a monoclonal antibody that imitates natural substances and accelerates the human immune system to attack the disease causing. Bangalore based Biocon is a research‐driven, global healthcare company with a strong atrix of capabilities along the biopharmaceutical value chain with prime focus on edical needs in the field of cancer, diabetes and inflammatory diseases.

mm


Industry Expert Speak Microbix and Zydus Cadila agreement to popularize Urokinase in North America William J. Gastle, Chief Executive Officer, Microbix Biosystems "Microbix has been the champion of Urokinase and we are committed to returning this life saving therapy to physicians and patients. We have been investing to rebuild this franchise including manufacturing infrastructure, raw materials, and technical expertise, in addition to acquiring the approved NDA's for both Canada and the US arkets. With Zydus, we now have a strong commercial partner to help us realize our bjective." mo Fortis Healthcare India and Super Religare Laboratories association will propel medical inclusion for Fortis – Shivinder Mohan Singh, MD, Fortis Healthcare (India) “We see great benefit in augmenting the Fortis presence with new speciality‐based verticals. The addition of diagnostics and retail dialysis will serve to enhance the quality of care to our customers. Most importantly, the new structure is a meaningful step toward Medical Inclusion in India and will help us offer value‐based medicine. This will better enable Fortis to deliver comprehensive and quality healthcare, with end to end service; thus taking us a step closer to our goal of reliable, affordable and accessible medical services for all.” Biocon Limoted tastes success in psoriasis treatment – Biocon Chairman Kiran MazumdarShaw “This could possibly become the first novel biologic developed and approved from ndia and is an important milestone for Biocon. We look forward to taking this olecule to the market across multiple indications with a global partner.”

Im


Transactions (November 2011 – January 2012)

Date Buyer Target Deal Size (INR mn) % stake Deal Status

Type of Transaction

1 8th Jan2012

Olympus Capital DM Healthcare 5000 NA Planned Private Equity

1 6th Jan2012

Life Healthcare Max Healthcare Institute Ltd.

5165 26% Planned M&A

12th Jan 2012

Fortis Healthcare (India) Ltd

Fortis Healthcare International

34885 100% Completed M&A

2 nd Dec2011

Vivimed Labs Uquifa 2840 100% Completed M&A

1st Nov 2011

Fortis Healthcare India

Fortis Healthcare International

33250 100% Planned M&A

28 v th No2011

Fidelity Growth Partners India

XC n ytoDiagn s Pvt ostic

Ltd. 200 NA Completed Private Equity

Annual Financial Results – Revenue (INR mn) – Major Healthcare Companies

Companies FY ‘08 FY ‘09 FY ‘10 FY ‘11

Abott India 6 ,763.60 7,822.70 9,406.60 9 ,373.90

Advanced Micronic Devices Ltd. 524.21 585.812 660.023 718.23



Ajanta Pharma Ltd. 3,093.70 3,493.40 4,091.40 5,048.70

Albert David Ltd. 1,596.42 1,851.75 2,029.58 2,184.95

Alembic Ltd. 1 0,075.76 1 1,190.28 1 1,399.17 2,007.84

Amrutanjan Healthcare 744.317 906.738 897.789 1,054.09

Apollo Hospitals Enterprise Ltd. 12,163.50 16,142.10 20,264.70 26,053.50

Biocon Ltd. 10,738.90 16,492.50 23,932.70 27,947.70

Blue Star Ltd. 22,215.90 2 5,026.20 2 5,249.70 2 9,760.90

BPL Ltd. 2,090.50 1,293.10 1,185.30 2,296.70

Cadila Healthcare Ltd. 23,063.00 29,066.00 35,780.00 44,671.00

Cipla Ltd. 42,602.70 52,876.20 56,704.00 63,850.70

Claris Lifesciences Ltd. 7,521.60 7,435.30 7,523.40 NA

Dabur India Ltd. 23,657.20 28,122.40 3 3,958.00 40,817.40

Divi's Laboratories Ltd. 10,387.00 1 1,849.50 9,499.20 1 3,137.00

Morepen Laboratories Ltd. 1,477.70 1,854.80 2,121.80 2,293.40

Dr. Reddy’s Laboratories 49,448.00 6 9,441.00 7 0,277.00 7 4,693.00

Elder Pharmaceuticals Ltd. 5,512.00 6,242.30 7,284.10 9,648.50

FDC Ltd. 4,964.40 5,909.00 6,340.10 7,103.30

Fortis Healthcare India Ltd. 5,071.00 6,305.90 9,380.60 1 4,829.70

Fresenius Kabi Oncology Limited 2,688.00 3,257.20 4,884.80 5,255.60

GlaxoSmithKline Pharmaceuticals Ltd.

17,032.80 19,179.80 21,608.50 NA

Glenmark Pharmaceuticals Ltd. 19,800.00 2 1,241.20 2 5,291.30 2 9,490.70

Hikal Ltd. 4,866.60 5,728.70 5,389.50 5,023.00


Companies FY ‘08 FY ‘09 FY ‘10 FY 1 ‘1

Intas Pharmaceuticals Ltd. 9,236.70 11,266.20 16,172.30 NA

Jubilant Organosys 25,017.60 3 5,491.00 3 8,047.80 3 4,484.40

Kopran Ltd. 1,297.09 1,186.33 1,643.59 1,947.75

Larsen & Toubro Ltd. 292,1 18.60 4 01,949.60 4 35,285.30 5 15,624.40

Lupin Ltd. 2 8,708.50 3 8,508.30 4 8,318.10 5 7,851.90

Maestros Mediline Systems Ltd. 349.418 295.262 304.853 425.648

Nestle India 43,252.20 5 1,395.50 62,609.40 5,340.80

Opto Circuits (India) Ltd. 4,680.80 8,185.20 1 0,775.80 15,855.60

Panacea Biotec Ltd. 8,439.50 7,921.80 9,066.70 1 1,573.50

Pfizer Ltd. India 7,036.10 7944.1* NA 9,326.10

Philips Electronics India Ltd. 31,004.00 32,527.00 37,047.00 NA

Piramal Healthcare Ltd. 28,672.90 32,478.20 36,276.30 25,1 .70 57

Plethico Pharmaceuticals Ltd. 9,845.50 12,459.00 15,121.10 NA

Ranbaxy Laboratories Ltd. 74,1 .00 40 75,9 .40 70 8 9,607.70 87315.9*

Regency Hospital Ltd. NA NA 4 00.476 52 1 2.04

Shree Pacetronix Ltd. 58.355 59.139 62.078 NA

Siemens Ltd. 9 6,858.40 9 3,070.20 9 6,272.40 11 0 9,718.1

Span Diagnostics Ltd. 605.742 675.954 802.615 84 3 0.6

Strides Arcolab Ltd. 10,310.00 13,234.80 17,367.30 NA

Sun Pharmaceuticals Industries Ltd.

33,5 .30 65 4 2,723.00 3 8,086.30 57,2 .30 14

Super Religare Laboratories Ltd. NA 1,380.58 1,693.57 NA

Torrent Pharmaceuticals Ltd. 13,548.50 16,306.60 16,306.60 22,264.80



Twilight Litaka Pharma Ltd. 2,951.70 3,708.40 4 ,924.10 6,709.20

Vimta Labs Ltd. 766.939 816.032 868.0 2 957.0 13

Vista Pharmaceuticals 10.244 18.231 8.014 56.745

Wockhardt Ltd. 35,998.60 36294.4* 36,4 .60 77 37,6 .50 33

Zandu Realty Ltd. 1,687.50 877.461 NA NA

Annual Financial Results – Income (INR mn)

Companies F Y ‘08 F Y ‘09 F Y ‘10 F Y ‘11

Abott India 628.6 775.1 753* 562.5

Advanced Micronic Devices Ltd. 1 0.445 14.948 2.585 1 7.386

Ajanta Pharma Ltd. 218.8 254.3 340 507.1

Albert David Ltd. 73.397 75.263 102.74 108.458

Alembic Ltd. 1 ,121.93 108.17 395.378 ‐129.019

Amrutanjan Healthcare 50.27 923.94 114.717 102.119

Apollo Hospitals Enterprise Ltd. 771.6 1 ,024.90 1,375.70 1,839.20

Biocon Ltd. 4,639.10 931.2 2,932.40 3,675.20

Blue Star Ltd. 1,740.90 1,8 0 02.9 2, 0 114.9 1 ,609.70

BPL Ltd. ‐1,456.90 39.4 ‐33.7 758.4

Cadila Healthcare Ltd. 2,576.00 3,031.00 5,051.00 7,110.00

Cipla Ltd. 7,010.40 7,710.20 10,825.90 9,895.70

Claris Lifesciences Ltd. 1,079.00 1,303.70 1,414.40 NA



Dabur India Ltd. 3,331.30 3,905.00 5,010.80 5,685.70

Divi's Laboratories Ltd. 3,476.00 4,166.40 3,403.40 4,292.70

Morepen Laboratories Ltd. ‐548.6 ‐417.6 ‐62.2 ‐469.4

Dr. Reddy’s Laboratories 3,846.00 ‐5,168.00 1,068.00 11,040.00

Elder Pharmaceuticals Ltd. 697.1 608.3 495 642.2

FDC Ltd. 631.7 862.1 1,491.30 1,508.90

Fortis Healthcare India Ltd. ‐368.9 208.2 694.8 1,243.60

Fresenius Kabi Oncology Limited 985.9 ‐1,460.20 ‐333.6 160.1

GlaxoSmithKline Pharmaceuticals Ltd.

5,910.90 5,078.60 5,605.70 NA

Glenmark Pharmaceuticals Ltd. 6,321.30 1,916.60 3,244.70 4,532.10

Hikal Ltd. 477.6 405 72.9 370.2

Intas Pharmaceuticals Ltd. 763.3 923.2 2,058.20 NA

Jubilant Organosys 4,004.90 2,831.80 4,214.60 2,297.20

Kopran Ltd. 72.824 ‐137.893 68.993 45.344

Larsen & Toubro Ltd. 23,253.60 37,894.60 54,507.40 44,561.70

Lupin Ltd. 4,082.50 5,015.40 6,816.30 8,625.50



Maestros Mediline Systems Ltd. 5.189 2.547 5.976 36.701

Nestle India 6,550.00 8,186.60 NA NA

Opto Circuits (India) Ltd. 1,306.60 2,087.30 2,603.00 3,672.50

Panacea Biotec Ltd. 1,289.80 ‐654.8 817.2 1,446.70

Pfizer Ltd. India 2,995.70 1371.2* NA 1,697.60

Philips Electronics India Ltd. 1,351.00 1,175.00 889 NA

Piramal Healthcare Ltd. 3,337.80 3,162.50 4,819.00 128,833.60

Plethico Pharmaceuticals Ltd. 1,233.60 2,169.30 2,444.00 NA

Ranbaxy Laboratories Ltd. ‐9,512.10 2,964.90 14,967.50 ‐144.4

Regency Hospital Ltd. NA NA 11.34 22.342

Shree Pacetronix Ltd. 2.663 1.586 1.11 NA

Siemens Ltd. 5,995.50 7,046.00 7,577.70 8,677.50

Span Diagnostics Ltd. 27.258 12.588 54.534 54.897

Strides Arcolab Ltd. 1,079.60 1,096.80 1,224.50 NA

Sun Pharmaceuticals Industries Ltd.

14,869.00 18,177.30 13,510.80 18,160.60

Super Religare Laboratories Ltd. NA ‐36.48 ‐336.06 NA



Torrent Pharmaceuticals Ltd. 1,346.80 1,843.70 2,312.00 2,701.70

Twilight Litaka Pharma Ltd. 180.3 219.4 326.3 512.5

Vimta Labs Ltd. 62.457 40.443 26.586 ‐46.651

Vista Pharmaceuticals ‐8.846 ‐9.616 ‐13.502 ‐2.922

Wockhardt Ltd. ‐1,388.60 ‐4355.4* ‐9,804.20 905.2

Zandu Realty Ltd. 164.83 152.549 13.906 9.144

* denotes a change in financial year

Events Calendar

62n f Indiand Annual National Conference o A ational He

Date: 1sssociation of Occupt

alth February – 4th February 2012

Venue: India Habitat Centre Organiser: Indian Association of Occupational Health, Delhi State

Contact PersWebsite: http://www.iaohindia.com

Contact ID: on: Rajiv Garg

ivgarg37@gmdrraj ail.com Contact No.: +91 120 4160240

In er ologt national Conference on Path y Date: 2nd February – 4th February 2012 Venue: Goa Medical College Organiser: Indian Academy of Cytologists with European Federation of Cytology Societies and International Academy of Cytology

Healthcare India 2012 Date: 20th FVenue: Indi

ebruary – 23rd February 2012 a Habitat Centre

Organiser: IIT De lhi and Jamia HamdardWebsite: htt 2012.orgp://www.healthcareindia Contact Person: Prof. Bhuvane

[email protected] Gupta

Contact ID: bgup .ernet.in Contact No.: +91 11 26591416

I CONPHA 2012 56 h Annual Natiot nal Confe ciation r blic Health AssoDate: 10

ence of Indian Puth February – 12th February 2012

Venue: IMA House, Kochi Organiser: Indian Public Health Association Kerala State Branch Website: htt omp://www.iphacon2012.c Contact Person: Arun S

pha mContact ID: i con2012@g ail.com Contact No.: +91 9846329898


Research on India (ROI) is a leading source for market research on various sectors in ndia that offers premium research content from worldwide publishers of market Iresearch reports. For any queries, contact us: W: https://www.researchonindia.com el: India (Toll Free): 1800 102 1133; Inmail: TE

ternational: +91 (33) 4027 6214/5 [email protected]

Connect with Us

Disclaimer: This monthly update is published for general information only based on press articles and company releases. Research on India has not independently verified any of information and is not responsible for any loss or damage arising from use of this document


http://www.facebook.com/researchonindia

https://twitter.com/ResearchOnIndia

http://www.linkedin.com/groups?gid=3280715&trk=hb_side_g

research on india_healthcare sector in india monthly update_january 2012

Documents